Show simple item record

dc.contributor.authorKvivik, Ingeborg
dc.contributor.authorGrimstad, Tore Bjørn
dc.contributor.authorJonsson, Grete
dc.contributor.authorKvaløy, Jan T.
dc.contributor.authorOmdal, Roald
dc.date.accessioned2021-08-20T10:53:13Z
dc.date.available2021-08-20T10:53:13Z
dc.date.created2021-07-16T16:09:26Z
dc.date.issued2021
dc.identifier.issn1753-4259
dc.identifier.urihttps://hdl.handle.net/11250/2770553
dc.description.abstractFatigue is common in all chronic inflammatory and autoimmune diseases. A conceptual model for understanding the biological basis of fatigue describes it as being a part of the sickness behaviour response generated by pro-inflammatory cytokines and other mediators. We hypothesised that the pro-inflammatory high mobility group box 1 (HMGB1) protein is a fatigue-inducing molecule and that auto-Abs against HMGB1 reduce fatigue. We measured Abs against disulphide (ds) HMGB1 and fully reduced (fr) HMGB1 in plasma from 57 patients with Crohn’s disease. Fatigue was rated using the fatigue visual analogue scale (fVAS) and disease activity with faecal calprotectin, C-reactive protein and the Simple Endoscopic Score for Crohn’s disease. Multivariable regression models identified anti-dsHMGB1 and anti-frHMGB1 Abs as the strongest contributing factors for fVAS scores (B = −29.10 (P = 0.01), R2 = 0.17, and B = −17.77 (P = 0.01), R2 = 0.17, respectively). Results indicate that anti-HMGB1 auto-Abs alleviate fatigue possibly by down-regulating HMGB1-induced sickness behaviour.en_US
dc.language.isoengen_US
dc.publisherSageen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAnti-HMGB1 auto-Abs influence fatigue in patients with Crohn’s diseaseen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Authorsen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1177/17534259211014252
dc.identifier.cristin1921961
dc.source.journalInnate Immunityen_US
dc.source.pagenumber286-293en_US
dc.identifier.citationInnate Immunity. 2021, 27 (4), 286-293.en_US
dc.source.volume27en_US
dc.source.issue4en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal